All data are based on the daily closing price as of September 17, 2025
e
EirGenix
6589.TWO
2.02 USD
0.01
+0.50%
Overview
Last close
2.02 usd
Market cap
610.39M usd
52 week high
2.98 usd
52 week low
1.60 usd
Target price
4.6 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
20.6708
Price/Book Value
2.1404
Enterprise Value
541.98M usd
EV/Revenue
17.0297
EV/EBITDA
-32.1413
Key financials
Revenue TTM
32.35M usd
Gross Profit TTM
7.27M usd
EBITDA TTM
-23.68M usd
Earnings per Share
-0.08 usd
Dividend
N/A usd
Total assets
355.91M usd
Net debt
N/A usd
About
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.